Trial Profile
A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) in Neonates With ≥36 Weeks GA With Moderate to Severe Perinatal Asphyxia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 May 2017
Price :
$35
*
At a glance
- Drugs 2-iminobiotin (Primary)
- Indications Asphyxia
- Focus Biomarker; Therapeutic Use
- Sponsors Neurophyxia
- 23 May 2017 Status changed from active, no longer recruiting to discontinued.
- 22 Apr 2015 New trial record